![]() |
市場調查報告書
商品編碼
1692400
胃滯留藥物輸送系統外包市場 - 全球產業規模、佔有率、趨勢、機會和預測,按劑型(片劑、液體、微球、膠囊等)區域和競爭細分,2020-2030 年Gastroretentive Drug Delivery Systems Outsourcing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Dosage Form (Tablets, Liquid, Microspheres, Capsule, Others) Region and Competition, 2020-2030F |
2024 年全球胃滯留藥物輸送系統外包市場價值為 13.7 億美元,預計到 2030 年將達到 18.9 億美元,預測期內複合年成長率為 5.51%。全球胃滯留藥物輸送系統外包市場是製藥和醫療保健產業內一個充滿活力且快速發展的產業。胃滯留給藥系統是指使藥物能夠在胃中停留較長時間的專門配方和技術,從而實現控制釋放和標靶治療效果。由於對提高藥物生物利用度、改善患者依從性並減少副作用的新型藥物輸送系統的需求不斷增加,該細分市場正在經歷顯著成長。
市場概況 | |
---|---|
預測期 | 2026-2030 |
2024 年市場規模 | 13.7 億美元 |
2030 年市場規模 | 18.9 億美元 |
2025-2030 年複合年成長率 | 5.51% |
成長最快的領域 | 平板電腦 |
最大的市場 | 北美洲 |
胃腸道疾病等慢性疾病的發生率不斷上升,需要有效且患者友善的藥物傳遞解決方案。此外,人口老化和對先進製藥技術認知的不斷提高正在推動對胃滯留藥物輸送系統的需求。製藥業擴大將這些系統的開發和製造外包給專門的合約研究組織(CRO)和合約製造組織(CMO),以利用他們的專業知識並縮短產品上市時間。
該市場的特點是外包服務種類繁多,包括配方開發、臨床前和臨床測試以及胃滯留藥物輸送系統的商業規模生產。 CRO 和 CMO 在提供涵蓋研發、技術選擇、法規遵循和品質保證的端到端解決方案方面發揮關鍵作用。因此,製藥公司可以專注於藥物發現和臨床開發的核心競爭力,同時依靠外包合作夥伴來獲得胃滯留藥物輸送的專業知識。
此外,區域擴張、策略合作以及研發活動的投資也促進了市場的快速成長。隨著新型胃滯留藥物傳遞技術的發展,市場正在經歷創新的熱潮,包括漂浮系統、生物黏合系統和可擴展系統。
胃腸道疾病盛行率上升
智慧財產權問題
靶向藥物傳輸需求不斷成長
Global Gastroretentive Drug Delivery Systems Outsourcing Market was valued at USD 1.37 billion in 2024 and is expected to reach USD 1.89 billion by 2030 with a CAGR of 5.51% during the forecast period. The Global Gastroretentive Drug Delivery Systems Outsourcing Market is a dynamic and rapidly evolving sector within the pharmaceutical and healthcare industry. Gastroretentive drug delivery systems refer to specialized formulations and technologies that enable drugs to be retained in the stomach for an extended period, facilitating controlled release and targeted therapeutic effects. This market segment is witnessing significant growth due to the increasing demand for novel drug delivery systems that enhance drug bioavailability, improve patient compliance, and reduce side effects.
Market Overview | |
---|---|
Forecast Period | 2026-2030 |
Market Size 2024 | USD 1.37 Billion |
Market Size 2030 | USD 1.89 Billion |
CAGR 2025-2030 | 5.51% |
Fastest Growing Segment | Tablets |
Largest Market | North America |
the rising prevalence of chronic diseases, such as gastrointestinal disorders, which require effective and patient-friendly drug delivery solutions. Moreover, an aging population and increasing awareness of advanced pharmaceutical technologies are propelling the demand for gastroretentive drug delivery systems. The pharmaceutical industry is increasingly outsourcing the development and manufacturing of these systems to specialized contract research organizations (CROs) and contract manufacturing organizations (CMOs) to leverage their expertise and reduce time-to-market.
The market is characterized by a diverse range of outsourcing services, including formulation development, preclinical and clinical testing, and commercial-scale production of gastroretentive drug delivery systems. CROs and CMOs are playing a pivotal role in offering end-to-end solutions that encompass research and development, technology selection, regulatory compliance, and quality assurance. As a result, pharmaceutical companies can focus on their core competencies in drug discovery and clinical development, while relying on outsourcing partners for specialized expertise in gastroretentive drug delivery.
Furthermore, regional expansion, strategic collaborations, and investments in research and development activities are contributing to the market's rapid growth. The market is witnessing a surge in innovation, with the development of novel gastroretentive drug delivery technologies, including floating systems, bio adhesive systems, and expandable systems.
Key Market Drivers
Rising Prevalence of Gastrointestinal Disorders
The rising prevalence of gastrointestinal disorders is a pivotal driver behind the growth of the Global Gastroretentive Drug Delivery Systems Outsourcing Market. Gastrointestinal conditions, such as gastroesophageal reflux disease (GERD), irritable bowel syndrome (IBS), inflammatory bowel disease, and peptic ulcers, are becoming increasingly common worldwide. These disorders can significantly impact an individual's quality of life and managing them effectively often requires specialized pharmaceutical interventions.
According to World Gastroenterology Organisation, overall, 49% of females and 36.6% of males met criteria for at least one FGID - the most common disorders in all regions being functional constipation, functional dyspepsia, proctalgia fugax, functional diarrhea and IBS at prevalence rates of 11.7%, 7.2%, 5.9%, 4.7% and 4.1, respectively.
Gastroretentive drug delivery systems play a crucial role in addressing the challenges associated with treating gastrointestinal disorders. These innovative systems allow drugs to remain in the stomach for an extended period, ensuring localized treatment and controlled release of therapeutic agents. This approach not only enhances the bioavailability of drugs but also minimizes side effects and maximizes the effectiveness of treatment, providing much-needed relief to patients suffering from gastrointestinal ailments.
Key Market Challenges
Intellectual Property Concerns
In the competitive world of pharmaceuticals, companies invest heavily in research and development to create proprietary innovations, including gastroretentive drug delivery technologies. These innovations often form the core of their product portfolio and protecting them through IP rights is essential for maintaining a competitive edge. The fear of losing exclusive rights to these innovations can lead to hesitancy in sharing proprietary information with outsourcing partners, potentially hampering collaboration.
Collaborations between pharmaceutical companies and contract research organizations (CROs) or contract manufacturing organizations (CMOs) require a degree of information exchange. For the successful development and manufacturing of gastroretentive drug delivery systems, there's a need to share critical data, formulation knowledge, and technical expertise. However, striking the right balance between knowledge sharing and IP protection can be challenging. Pharmaceutical companies must carefully manage their IP while ensuring that their outsourcing partners have the necessary information to deliver high-quality products.
Key Market Trends
Increasing Demand for Targeted Drug Delivery
The Global Gastroretentive Drug Delivery Systems Outsourcing Market is experiencing a significant boost due to the increasing demand for targeted drug delivery solutions. This surge in demand is fueled by several factors and represents a key driving force shaping the future of the pharmaceutical outsourcing industry.
One of the most prominent factors driving the increasing demand for targeted drug delivery is the growing recognition of the limitations of traditional drug delivery methods. Conventional oral drug delivery often lacks specificity, with drugs being absorbed throughout the gastrointestinal tract. This can lead to reduced drug bioavailability and increased side effects, making it less than ideal for many therapeutic applications.
gastroretentive drug delivery systems offer a highly effective means of targeting specific regions within the gastrointestinal tract, particularly the stomach. These systems allow drugs to remain in the stomach for an extended duration, ensuring that they are delivered precisely where they are needed. This localized, site-specific approach not only enhances drug bioavailability but also minimizes unwanted side effects, improving the overall therapeutic outcomes for patients.
In this report, the Global Gastroretentive Drug Delivery Systems Outsourcing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies present in the Global Gastroretentive Drug Delivery Systems Outsourcing Market.
Global Gastroretentive Drug Delivery Systems Outsourcing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: